BioSpace News Archive

Cure Rare Disease has been awarded an advocacy collaboration grant from the Muscular Dystrophy Association to support research on novel reimbursement strategies for drugs developed for ultra-rare diseases, a key challenge for rare disease patients, including muscular dystrophy patients.

Sparta Science, the enterprise leader in Movement Health Intelligence, announced it is partnering with researchers from La Trobe University and Sheffield Hallam University on a collaborative project looking into the effect of head impact exposure on brain health and movement adaptability.

Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”) today announced the presentation of blinded safety and pharmacokinetic (PK) data from the ongoing Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).

Merck’s KEYTRUDA ® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression.

Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, informs its shareholders that its extraordinary shareholder meeting, convened a second call to vote on the same agenda as the extraordinary shareholder meeting of February 15, 2023.

Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it will be attending the 2nd GPCR-Targeted Drug Discovery Summit in Boston from February 21st-23rd.

The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.48 per share.

Medical device and technology company Lazurite announced that Laith Jazrawi, M.D. and Mark Schickendantz, M.D. have joined the company’s medical advisory board.

Subgroup analyses from the pivotal Phase III ARASENS trial support overall survival (OS) benefits of NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) and docetaxel compared to ADT and docetaxel in patients with high-volume and high and low-risk metastatic hormone-sensitive prostate cancer (mHSPC).

NeuroMetrix, Inc. announced that it plans to issue its 2022 fourth quarter and year end financial results before the opening of the market on February 23, 2023.